

AMENDMENTS TO CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Original) A method for preparing a donor cell, tissue, or organ for transplantation into a recipient, said method comprising reducing intracellular lipid storage material of said cell, tissue, or organ.
2. (Original) The method of claim 1, wherein a donor cell is prepared.
3. (Original) The method of claim 1, wherein a donor tissue is prepared.
4. (Original) The method of claim 1, wherein a donor organ is prepared.
5. (Original) The method of claim 1, wherein said cell is a liver cell, said tissue is a liver tissue, or said organ is a liver.
6. (Original) The method of claim 1, wherein said method comprises contacting said cell, tissue, or organ with a solution that increases oxidation of a lipid; increases export of a lipid from said cell, tissue, or organ; or both.
7. (Original) The method of claim 1, wherein said intracellular lipid storage material is a triglyceride, a cholesterol, a cholesterol ester, or a phospholipid.
8. (Original) The method of claim 1, wherein said method results in reducing an ischemia-reperfusion injury in said cell, tissue, or organ upon transplantation into a recipient.
9. (Original) The method of claim 1, wherein said method results in reducing a cold-preservation-related injury in said cell, tissue, or organ upon transplantation into a recipient.

10. (Original) The method of claim 1, wherein said method reconditions a steatotic cell, tissue, or organ.

11. (Original) The method of claim 10, wherein said steatotic cell is a liver cell, said steatotic tissue is liver tissue, or said steatotic organ is a liver.

12. (Original) The method of claim 1, further comprising inducing heat shock of said cell, tissue, or organ.

13. (Original) The method of claim 12, wherein said inducing is the result of increasing the temperature of said cell, tissue, or organ by at least 1⁰C for at least one minute.

14. (Original) The method of claim 13, wherein said temperature is increased for a period ranging between one minute and one hour.

15. (Cancelled)

16. (Cancelled).

17. (Original) The method of claim 13, wherein said temperature of said cell, tissue, or organ is increased to a range between 37⁰C and 50⁰C.

18-20. (Cancelled)

21. (Original) The method of claim 13, wherein said increasing of said temperature is the result of heating the whole body of the donor of said cell, tissue, or organ.

22. (Original) The method of claim 13, wherein said increasing of said temperature is the result of heating a localized area of the donor including said cell, tissue, or organ.

23. (Currently amended) The method of claim ~~21 or 22~~ 13, wherein said heating is mediated by microwave or ultrasound treatment.

24. (Original) The method of claim 22, wherein said heating is mediated by warming the blood percolating said localized area.

25. (Currently amended) The method of claim ~~21 or 22~~ 13, wherein said increasing of said temperature is the result of heating said cell, tissue, or organ *ex vivo*.

26. (Original) The method of claim 12, wherein said inducing is the result of contacting said cell, tissue, or organ with an agent that increases the expression of at least one heat shock protein in said cell, tissue, or organ.

27. (Original) The method of claim 26, wherein said agent is cobalt protoporphyrin or geranylgeranylacetone.

28. (Original) The method of claim 26, wherein said cell, tissue, or organ is provided with at least one expression vector comprising a nucleic acid sequence encoding a heat shock protein.

29. (Original) The method of claim 1, further comprising administering a heat shock protein to said cell, tissue, or organ.

30. (Currently amended) The method of claim ~~28 or 29~~ 26, wherein said heat shock protein is selected from the group consisting of HSP72, HSP70, HO-1, and HSP90.

31-35. (Cancelled)

36. (Currently amended) The method of claim 1, ~~12, 28, or 29~~, further comprising contacting said cell, tissue, or organ with a composition comprising gadolinium chloride (GdCl₃).

37. (Currently amended) The method of claim 1, ~~12, 28, or 29~~, further comprising contacting said cell, tissue, or organ with a composition comprising an agent that inhibits the proliferation, activation, or both of T cells.

38. (Original) The method of claim 37, wherein said agent is selected from the group consisting of cyclosporine A (CyA) and FK506.

39-42. (Cancelled)

43. (Original) A solution for reducing intracellular lipid storage material of a donor cell, tissue, or organ comprising a catabolic hormone and an amino acid, wherein said catabolic hormone is selected from the group consisting of glucagon, epinephrine, growth hormone, hepatocyte growth factor, leptin, adiponectin, metformin, thyroid hormone, and a glucocorticoid hormone and wherein said amino acid is selected from the group consisting of alanine and glutamine.

44-62. (Cancelled)

63. (Original) A method for preparing a donor cell, tissue, or organ for transplantation into a recipient, said method comprising contacting said donor cell, tissue, or organ with the solution of claim 43.

64-87. (Cancelled)